. 2020 Feb 14;11:40. doi: 10.3389/fphar.2020.00040
Copyright © 2020 Yang, Jin, Pang, Huang, Wang, Zhang, Tuo, Wu, Wang and Zhu
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Figure 6.
Forest plot of nivolumab plus ipilimumab vs. nivolumab for prolonging mOS.